09:26:08 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande



2025-02-03 Bokslutskommuniké 2024
2024-11-01 Kvartalsrapport 2024-Q3
2024-08-15 Kvartalsrapport 2024-Q2
2024-05-02 Kvartalsrapport 2024-Q1
2024-04-25 Årsstämma 2024
2024-02-29 Bokslutskommuniké 2023
2023-11-30 Kvartalsrapport 2023-Q3
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-31 Kvartalsrapport 2023-Q1
2023-05-12 Ordinarie utdelning BRAIN 0.00 SEK
2023-05-11 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2023-02-15 Extra Bolagsstämma 2022
2022-11-30 Kvartalsrapport 2022-Q3
2022-08-31 Kvartalsrapport 2022-Q2
2022-05-31 Kvartalsrapport 2022-Q1
2022-05-12 Ordinarie utdelning BRAIN 0.00 SEK
2022-05-11 Årsstämma 2022
2022-02-28 Bokslutskommuniké 2021
2021-11-30 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-31 Kvartalsrapport 2021-Q1
2021-04-16 Ordinarie utdelning BRAIN 0.00 SEK
2021-04-15 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-11-27 Kvartalsrapport 2020-Q3
2020-08-28 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning BRAIN 0.00 SEK
2020-06-30 Årsstämma 2020
2020-05-29 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-08 Kvartalsrapport 2019-Q3
2019-08-30 Kvartalsrapport 2019-Q2
2019-06-17 Årsstämma 2019
2019-04-08 Ordinarie utdelning BRAIN 0.00 SEK
2019-02-28 Bokslutskommuniké 2018
2018-11-16 Kvartalsrapport 2018-Q3
2018-08-27 Kvartalsrapport 2018-Q2
2018-07-25 Extra Bolagsstämma 2018
2018-05-09 Kvartalsrapport 2018-Q1
2018-04-19 Ordinarie utdelning BRAIN 0.00 SEK
2018-04-18 Årsstämma 2018
2018-02-16 Bokslutskommuniké 2017
2017-11-23 Kvartalsrapport 2017-Q3
2017-08-10 Kvartalsrapport 2017-Q2
2017-06-29 Årsstämma 2017
2017-05-15 Kvartalsrapport 2017-Q1
2017-04-24 Extra Bolagsstämma 2017
2017-04-12 Ordinarie utdelning BRAIN 0.00 SEK
2017-02-14 Bokslutskommuniké 2016
2016-11-10 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-10 Kvartalsrapport 2016-Q1
2016-04-14 Årsstämma 2016
2016-03-27 Ordinarie utdelning BRAIN 0.00 SEK
2016-01-28 Bokslutskommuniké 2015
2015-10-22 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2015-04-28 Kvartalsrapport 2015-Q1
2015-03-27 Ordinarie utdelning BRAIN 0.00 SEK
2015-03-26 Årsstämma 2015
2015-01-27 Bokslutskommuniké 2014
2014-10-20 Kvartalsrapport 2014-Q3
2014-08-19 Kvartalsrapport 2014-Q2
2014-06-26 Ordinarie utdelning BRAIN 0.00 SEK
2014-06-25 Årsstämma 2014
2014-04-14 Extra Bolagsstämma 2014


ListaFirst North Stockholm
BrainCool är verksamt inom medicinteknik. Bolaget utvecklar produkter som används inom medicinsk kylning av hjärnan. Teknologin är utvecklad som kylkuddar som appliceras på olika delar av patientens kropp, där systemet kontrollerar kroppstemperaturen. Produkterna används vid behandling av olika allvarliga tillstånd innefattande stroke, hjärtstopp, samt hjärnskakning och migrän. BrainCool grundades 2010 och har sitt huvudkontor i Lund.
2023-08-28 08:45:00

BrainCool Group
The period in brief

Apr-Jun 2023Jan-Jun 2023Full Year 2022
Net Sales7 36610 03417 588
EBITDA-11 001-25 259-31 924
EBIT-12 183-27 635-36 679
Result after tax-12 715-28 351-45 584
Cashflow from operating activities-13 144-38 592-46 269
Cash at the end of period88688641 206
Result per share-0,08-0,18-0,61*
All numbers are ksek
*Includes paid but not registered shares

CEO Martin Waleij, comments

BrainCool continued its high pace of expansion in several areas in the second quarter as well as after the accounting period. A milestone was the breakthrough deal with the American corporation ZOLL® announced in May. The deal with ZOLL® worth at least SEK 100 million is a distributor- and partner agreement concerning distribution, marketing, and sales of BrainCool™/IQool™ System stretching to 2030. The agreement applies to the markets in the U. S, Germany, Austria, Switzerland, and the Netherlands and implies an initial fixed order of 350 systems and a significant number of cooling plates over 18-24 months period. Deliveries will start on April 1, 2024.

The cooperation with ZOLL® has developed in a very positive way. In July BrainCool received an additional order of consumables from ZOLL® following the order of 20 IQool™ System in June. ZOLL® officially launched the partnership in the U. S in July. We are positive about the rapid development with ZOLL® and assess that several orders can be received before the large rollout is planned from Q1 2024.

We started already in June to reorganize the direct sales organization in the US. Five employees have had their assignments terminated and two more have been offered positions within our partner organization. By the second quarter of 2024 the restructure of the sales organization and supply chain in the U. S will result in savings of SEK 25 million, compared to our US personnel cost budget prior to the deal with ZOLL®. We are now working intensely on scaling up production of BrainCool™/IQool™ System to meet higher volumes in the U. S and the EU. Higher volumes will result in lower cost per unit produced.

The company´s rapid expansion requires capital. A direct share issue of SEK 60 million was conducted on the 28th of August. The new issue is aimed at strategic and institutional investors. The share issue and new shareholders confirm a firm confidence in BrainCool and its future potential. In August BrainCool informed the market that it had applied for 13 million euro in “soft” funding from EIB in order to finance various activities such as clinical studies within ultra-early cooling. In May the company secured SEK 20 million in a revolving credit facility that can be used if needed.

BrainCool has developed a new smaller version of RhinoChill® – MiniChill. The size and weight have been reduced significantly, from 15 kg to only 5kg. The new version will be easier to handle and creates new possibilities such as the miliary market and heat stroke. A new patent application for MiniChill was filed in July.

We are also aiming for establishing the use of cooling and RhinoChill® as a medical indication when treating stroke with thrombectomy. BrainCool has initiated a study encompassing 400 patients. The study will be made in cooperation with the university hospital in Freiburg and it will be financed by means from the EU. In July, we obtained ethical approval of the clinical study, and it will be completed by the first quarter in 2025. In June, the U. S Food and Drug Administration (FDA) granted RhinoChill® status as a “Breakthrough Device” for early cooling of stroke patients treated with thrombectomy. This paves the way for a fast-track market approval and opens for reimbursement in the U. S.

The U. S Administration also presented in June a new proposal for reimbursement aimed at “Breakthrough Device” products called Transitional Coverage for Emerging Technologies (TCET). If TCET is approved by the Congress, it may be very beneficial for BrainCool.

In the spring we launched a new commercialization strategy in the U. S for the new cooling product Cooral® System supporting patients undergoing treatment for cancer. The strategy is aiming for establishing reimbursement in the U. S.